Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

Gil Klinger, Yair Morad, Carol A. Westall, Carl Laskin, Karen A. Spitzer, Gideon Koren, Shinya Ito, Raymond J. Buncic

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic use of chloroquine and hydroxychloroquine in the treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugs during pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.

Original languageEnglish
Pages (from-to)813-814
Number of pages2
JournalThe Lancet
Volume358
Issue number9284
DOIs
StatePublished - 8 Sep 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases'. Together they form a unique fingerprint.

Cite this